Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma.

MLA

Yang, Yi-Wei, et al. “Ponatinib Is a Potential Therapeutic Approach for Malignant Pleural Mesothelioma.” Experimental Lung Research, vol. 47, no. 1, Feb. 2021, pp. 9–25. EBSCOhost, https://doi.org/10.1080/01902148.2020.1836691.

APA

Yang, Y.-W., Marrufo, A., Chase, J., Woodard, G. A., Jablons, D. M., & Lemjabbar-Alaoui, H. (2021). Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Experimental Lung Research, 47(1), 9–25. https://doi.org/10.1080/01902148.2020.1836691

Chicago

Yang, Yi-Wei, Angelica Marrufo, Jillian Chase, Gavitt A Woodard, David M Jablons, and Hassan Lemjabbar-Alaoui. 2021. “Ponatinib Is a Potential Therapeutic Approach for Malignant Pleural Mesothelioma.” Experimental Lung Research 47 (1): 9–25. doi:10.1080/01902148.2020.1836691.